Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Feb 15, 2019; 11(2): 117-138
Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.117
Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.117
Table 4 Levels of phenotypic antigen expression in healthy subjects and tumor patients
| HS | Men | Women | TP | Men | Women | |
| CD3 | 59.8 ± 1.3 | 60.9 ± 1.8 | 58.3 ± 1.9 | 49.0 ± 2.3 | 46.7 ± 2.8 | 52.4 ± 4.0 |
| CD8 | 25.3 ± 0.9 | 25.0 ± 1.3 | 26.1 ± 1.2 | 20.0 ± 1.3 | 19.2 ± 1.5 | 21.4 ± 2.3 |
| CD16 | 12.5 ± 1.1 | 16.5 ± 1.8 | 7.7 ± 0.8 | 15.5 ± 1.3 | 15.4 ± 1.5 | 14.7 ± 2.3 |
| CD56 | 11.8 ± 1.2 | 14.6 ± 1.9 | 8.5 ± 0.9 | 16.4 ± 1.6 | 17.5 ± 2.0 | 14.9 ± 2.5 |
| CD57 | 23.7 ± 1.2 | 25.9 ± 1.8 | 21.5 ± 1.3 | 23.7 ± 1.8 | 22.3 ± 1.8 | 26.2 ± 4.0 |
| CD3-CD56+ | 19.7 ± 0.1 | 19.7 ± 0.1 | 19.7 ± 0.1 | 12.7 ± 3.2 | 18.0 ± 5.5 | 7.3 ± 2.1 |
| CD8-CD57+ | 11.4 ± 1.6 | 12.4 ± 2.0 | 8.4 ± 2.2 | 7.2 ± 3.1 | 15.5 ± 0.1 | 4.5 ± 1.9 |
- Citation: Berghella AM, Aureli A, Canossi A, Beato TD, Colanardi A, Pellegrini P. Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer. World J Gastrointest Oncol 2019; 11(2): 117-138
- URL: https://www.wjgnet.com/1948-5204/full/v11/i2/117.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i2.117